CytoDyn Inc. (CYDY) Reports HIV Single Agent Therapy Progress Following Improved Response Rate at Higher Dose
PRO 140 single agent therapy is the first successful single agent therapy in the history of HIV for a sub-population of HIV Response rate for the company’s innovative PRO 140 nearly doubled after dosage increase About 70 percent of phase 3 trial participants treated with higher doses have achieved viral load suppression The monotherapy would allow patients to self-administer one dose per week of PRO 140 at home Biotechnology company CytoDyn Inc. (OTCQB: CYDY) has announced significant developmental progress for its PRO 140 monotherapy for human immunodeficiency virus (HIV) after noticing improved response rates at higher doses of the treatment…
